ariatric surgery in obese individuals has a demonstrable impact on cardiometabolic risk, with both early and late benefits on insulin resistance and cardiovascular disease (CVD) risk. Accordingly, examination of circulating biomolecules (eg, metabolites, circulating RNAs, and proteins) after bariatric weight loss surgery has yielded important insights into molecular pathways affected by changes in weight and accompanying improvement in insulin resistance. Indeed, clinical investigations using multiomic platforms during medical weight loss have suggested the fruitfulness of this paradigm for identifying metabolic, genomic, and epigenetic alterations that may prove to be critical in the pathogenesis of cardiometabolic disease. Nevertheless, although these efforts have been important in identifying reversible molecular signatures of obesity, whether or not such biomarkers are applicable to larger populations at risk for metabolic syndrome and diabetes mellitus remains unclear.
B
ariatric surgery in obese individuals has a demonstrable impact on cardiometabolic risk, with both early and late benefits on insulin resistance and cardiovascular disease (CVD) risk. Accordingly, examination of circulating biomolecules (eg, metabolites, circulating RNAs, and proteins) after bariatric weight loss surgery has yielded important insights into molecular pathways affected by changes in weight and accompanying improvement in insulin resistance. Indeed, clinical investigations using multiomic platforms during medical weight loss have suggested the fruitfulness of this paradigm for identifying metabolic, genomic, and epigenetic alterations that may prove to be critical in the pathogenesis of cardiometabolic disease. Nevertheless, although these efforts have been important in identifying reversible molecular signatures of obesity, whether or not such biomarkers are applicable to larger populations at risk for metabolic syndrome and diabetes mellitus remains unclear.
In this investigation, we examined selected proteins using serial nonfasting blood draws from a sample of individuals from a large study of bariatric surgery pre and postoperatively to identify specific proteins altered early (at ≈3 months) and late (at ≈12 months) postoperatively, relative to the preoperative state. To extend these results to a large at-risk population, we studied several proteins identified in the bariatric surgical study in a large number of participants from the FHS (Framingham Heart Study) to assess their association with incident metabolic syndrome and diabetes mellitus. Finally, using in silico approaches at the mRNA level, we identified potential tissues of origin for expression of genes encoding these proteins and suggest potential pathways targeted by them. Our ultimate aim was to use an integrated approach originating in an extreme phenotype (bariatric surgical weight loss) to identify potential biomarkers relevant to the development of insulin resistance, a major contributor to obesityrelated cardiometabolic disease.
Materials and Methods
Data from the FHS is publicly available at the dbGaP and can be accessed at https://www.ncbi.nlm.nih.gov/gap; data from the bariatric surgical study will not be made publically available.
Patient Cohorts

Bariatric Surgery
The analytic subsample for the present study was taken from a completed prospective cohort study aimed at understanding the effects of bariatric surgery on platelet function (U54-HL12311; Principal Investigator: J.E. Freedman). The parent study enrolled 121 individuals scheduled for clinically indicated bariatric surgery (either sleeve gastrectomy or gastric bypass surgery). Of note, 1 individual enrolled in the study and had preoperative measures but did not proceed to surgery or study follow-up. Study participants were examined preoperatively and at visits that were planned at ≈3 and 12 months postoperatively, with 98 participants with follow-up and blood samples at all 3 time points. Nonfasting peripheral venous blood was drawn into citrate tubes, with plasma isolated as described. 1 Samples were immediately stored at our high-throughput biomarker facility (not thawed until immediately before assay). Study investigators performed a medical history (medications, demographics, metabolic risk factors) and a physical examination. Hypertension was defined as the use of antihypertension medication or a systolic blood pressure (BP) >140 mm Hg or a diastolic BP >90 mm Hg. A diagnosis of diabetes mellitus was defined as type 1 on insulin or type 2 on any medications or a hemoglobin A1c > 6.5% at the baseline visit.
The sampling strategy for the discovery (bariatric surgery) cohort was complex ( Figure I in the online-only Data Supplement). This project was part of pilot efforts in our laboratory to configure and optimize the Olink protein quantification platform. As such, only a specific set of proteins was quantified (see Protein quantification, below), and protein quantification occurred during 2 separate sessions (runs), leading to potential biases from batch effects. Accordingly, we only included individuals who had blood at all 3 time points (visit 1, 2, and 3), with proteins quantified on the same run; this would allow us to avoid increased noise by comparing proteins in the same participant across runs (eg, visit 1 from run 1 being compared with visits 2 and 3 at run 2). It is critical to note that samples chosen for each run were done so in a nonrandom fashion, attempting to enrich for relief in insulin resistance over time. Briefly, samples included in the current analysis from run 1 were comprised to individuals selected based on age ≤50 years and resolution of diabetes mellitus at postoperative visit (N=4; selected based on absolute reduction in hemoglobin A1c from visit 1 to visit 3) versus no diabetes mellitus (N=6). Serial samples on Run 2 included individuals with diabetes mellitus at baseline (1 with prediabetes mellitus) and a selection of individuals with greater magnitude of change in hemoglobin A1c over time postoperatively. Further details of selection strategy are in Figure I in the online-only Data Supplement. This approach yielded 10 subjects in the first run and 22 subjects in the second run. For the subjects included in our analytic cohort, the average time (with SD) between baseline study visit 1 and visit 2 (≈3-month visit) was 139±43 days; the average time between baseline study visit 1 and visit 3 (≈12 month-visit) was 417±49 days. All subjects provided informed consent in accordance with an approved Institutional Review Board protocol.
Framingham Heart Study
This aspect of the investigation utilized data from the proteomics project of the SABRe (Systems Approach to Biomarker Research) CVD initiative, which included 2784 Offspring cohort participants from the FHS who appeared for the seventh and eighth examinations and 3392 participants from the FHS Third Generation cohort who appeared for the first and second on-site examinations.
2 Briefly, the FHS is a community-based, prospective cohort study of individuals in Framingham, MA, with examinations every 4 to 8 years, with detailed data and sample collection methods, as well as assessment of CVD risk factors. 3, 4 We used the average of 2 measurements of resting, seated BP as the BP values in our analysis. Current smokers smoked at least 1 cigarette per day in the past year. Physical activity was described previously, 5 and we generated a dichotomous variable for sedentary lifestyle (defined as a physical activity score of ≤30). Finally, we abstracted self-reported educational attainment into a categorical variable of no college degree, had college or similar degree, and completion of college or higher degree. We excluded participants with missing data for age, sex, smoking, alcohol consumption, physical activity, education, fasting glucose, insulin measurements, and those with fasting status <8 hours. We defined diabetes mellitus as fasting blood glucose ≥126 mg/dL, use of medication for diabetes mellitus, or reported history of diabetes mellitus. We defined metabolic syndrome as the presence of at least 3 of 5 metabolic risk factors: (abdominal obesity: waist circumference ≥88 cm for women and ≥102 cm for men; high triglyceride levels: ≥150 mg/dL; low HDL [high-density lipoprotein] cholesterol: <50 mg/dL for women or <40 mg/dL for men; elevated BP: systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or current antihypertensive medication use; high fasting blood glucose ≥100 mg/ dl or current use of antidysglycemia medications). The final cohort for analysis consisted of 4877 participants for new-onset diabetes mellitus and 3971 for new-onset metabolic syndrome. Informed consent was provided by all study participants. The Boston University Medical Center Institutional Review Board approved the study protocol.
Protein Quantification
Bariatric Surgery
We used the Olink platform for this study, which employs a quantitative polymerase chain reaction technology called Proximity Extension Assay for protein quantification (Olink, Uppsala, Sweden). For this study, we tested the CVD II, CVD III, and cardiometabolic panels but did not include results from the CVD II panel because of poor assay performance (specifically, poorly performing control values); the proteins in the included panels are shown in Table I Table II in the online-only Data Supplement).
Step-by-step procedures and protocol for reporting for the Luminex assays have been published. 6 The practices to ensure adequate quality control included: (1) using triplicate approaches for defining acceptable ranges and distribution curve of protein concentrations; (2) preparing controls for low and high concentrations with multiple measurements by 5 scientists on different dates; (3) duplicate plasma sample measurements. The FHS assays demonstrated acceptable coefficients of variation (2.0%-9.5%) across 71 proteins. 2 Proteins were log-transformed for analysis. The list of proteins used in this analysis of FHS participants was limited to a subset of proteins that were significantly altered over time after surgery in the bariatric surgical cohort. Results of the assays for the proteins targeted in this study are provided in Table II in the online-only Data Supplement.
RNA-Sequence Analysis for Tissues of Origin
Whole transcriptome RNA-sequencing data from the EMBL-EBI's (European Molecular Biology Laboratory-European Bioinformatics Institute) RNA-Seq Atlas (Array Express ID: E-MTAB-2836) that consists of 32 tissues from 122 individuals was used to look for the corresponding gene expression profiles of these dysregulated proteins in normal tissues. Briefly, the fastqs downloaded from EMBL were aligned to the human genome (hg19, ENSEMBL version 75) using STAR (Spliced Transcripts Alignment to a Reference) aligner. 7 Only reads that are uniquely mapped were considered for read annotation to gene features. Reads were annotated with the ENSEMBL 75 gene transfer format file using Salmon. 8 Salmon provides both read counts and transcripts per million reads for each gene feature in the ENSEMBL gene transfer format. Normalization of read counts was conducted via a median ratio method in DESeq2 (Differential Expression in Sequencing). 9 Sex-specific tissues, such as endometrium, fallopian tube, placenta, ovary, testis, and prostate gland, were omitted. Fold change for each gene was computed by dividing expression in the tissue with the highest expression by the expression in the second highest expressing tissue across all tissues considered.
Pathway Analysis
The list of 19 proteins with differences in the visit 1 to visit 2 and visit 1 to visit 3 time point pre versus postbariatric surgery was processed for enrichment analysis. First, the list was expanded based on predicted functional partners provided by the STRING database 10 to add 10 proteins with similar functional characteristics in addition to interactions among the combined set. In Cytoscape, 11 a coherent network of 26 proteins was identified (16 of the 19 original proteins plus 10 added by STRING). This set of 26 proteins served as the input to test for functional enrichment across a number of biological ontology and pathway resources using the online tool, Enrichr.
12 Tabular results were downloaded for Gene Ontology: Biological Process, Jensen Disease Ontology, 13 and WikiPathways. 14 Representative terms of interest were selected from these results and plotted as a bar graph ranked by a score calculated from both P value and Z score.
Statistical Analysis
The statistical methods for this analysis consisted of several distinct steps: (1) analysis of differential expression of circulating proteins from bariatric surgical cohort (including correction for batch effects); (2) validation of selected overlapping, candidate proteins with new-onset diabetes mellitus in the FHS cohort; (3) analyses of potential tissue of origin, using RNA-sequencing, and potential pathways implicated by these proteins. Steps 1 and 2 are described below.
Step 3 is described above. 
Differential Expression of Proteins at Different Time Points After Bariatric Surgery
Selection of Proteins and Handling Below-Detection Limit Values
Batch Effect Correction and Differential Expression
The protein measurements were performed at 2 different time points (runs) for both panels. Before correcting for potential batch effects, the proteins MEPE (matrix extracellular phosphoglycoprotein) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) were removed from the analysis from the cardiovascular III panel (position of MEPE on the plate in the 2 runs was switched; the assay performance of the NT-proBNP was improved by the vendor in run 2). Characteristics of the 181 proteins (92 from cardiometabolic, 91 from CVD III, then excluding MEPE and NT-proBNP) is presented in Table III in the online-only Data Supplement along with the number of samples with expression below-detection limit, mean expression value and interquartile range for visit 1, visit 2, and visit 3 samples. As mentioned previously, 43 total proteins were filtered because of below-detection limit expression in >50% of included samples (4 from CVD III panel and 39 from the cardiometabolic panel). Of the remainder, proteins with below-detection limit expression data were included in analysis with a value of 0. Although we recognize, for all proteins included, principal components analysis on log 2 -transformed protein levels for the cardiovascular III panel revealed that there was a significant batch effect between run 1 and run 2, whereas there was no discernible batch effect for the cardiometabolic panel ( Figure II in the online-only Data Supplement). The batch effect correction between the 2 runs was performed for both panels using ComBat from the SVA package in R that uses an empirical Bayesian framework. 15 In the end, the combined data from both runs and panels yielded 139 proteins that were used for differential expression analysis using LIMMA package in R 16 (Table III in the online-only Data Supplement), a standard approach in gene expression from microarray experiments. We identified proteins differentially expressed between visit 1 (preoperative) and visit 2 (early postoperative) and between visit 1 and visit 3 (late postoperative) using a paired analysis with a Bonferroni correction to address type 1 error and multiplicity.
Validation of Selected Candidate Proteins With New-Onset Metabolic Syndrome or Diabetes Mellitus in the FHS
Clinical and demographic characteristics of the FHS study sample were calculated as mean (with SD) or median (with 25% and 75% interquartile values) for continuous variables and frequency for categorical variables. Of the 139 proteins included in differential expression analyses (above), 25 were measured in the FHS; of these, we found an overlap of 6 proteins (IGFBP-1 [insulin-like growth factor binding protein], IGFBP-2, P-selectin, CD163, LDL [low-density lipoprotein]-receptor, and PAI [plasminogen activator inhibitor]-1) with those differentially expressed between visit 1 and 2 and between visits 1 and 3 in the bariatric surgery study after Bonferroni correction for multiple testing. These 6 proteins were included in subsequent analyses in the FHS. We applied logistic regression models to measure the association of each candidate protein with new-onset metabolic syndrome or diabetes mellitus. Models were adjusted for baseline age, sex, education, current smoking status (as defined above), alcohol consumption, body mass index, fasting insulin, and physical activity. For new-onset diabetes mellitus, we also adjusted for baseline fasting glucose. For new-onset metabolic syndrome, we also adjusted for waist circumference, systolic and diastolic BPs, HDL cholesterol, triglyceride, and fasting glucose level at baseline. A 2-sided P<0.05 was statistical significant, and analyses were performed in SAS 9.4 (SAS Institute, Cary, NC) or R (http://www.r-project.org).
Results
Clinical Characteristics of the Bariatric Surgery Cohort
Baseline characteristics of the 32 participants from the bariatric surgery study included in our analysis, relative to the other nonincluded participants, are shown in Table 1 . The study sample consisted primarily of middle-aged white individuals (median age, 45 years; 47% female), with a median body mass index (BMI) 45.0 kg/m 2 (interquartile range, 40.4-50.2 kg/m 2 ). Over 50% of participants included in this study had diabetes mellitus or other obesity-related comorbidities (eg, hypertension). Consistent with the nonrandom selection of samples for this substudy (see Methods, above, under Patient cohorts), relative to subjects not included in this substudy, we found that subjects included were less likely to be female and had a more even distribution of type of bariatric surgery. The prevalence of diabetes mellitus was higher in the included subjects, as was the hemoglobin A1c (both P<0.0001), whereas the BMI was similar between the 2 groups. In the 32 subjects included in this analysis, BMI had fallen by a median 9.5 kg/m 2 by visit 2 (interquartile range of weight loss, 11.4-7.7 kg/m 2 ); by visit 3, the median BMI reduction was 13 Figure 1A shows a Volcano plot demonstrating relative fold change between visit 1 and visit 2 relative to significance level. Of note, 19 of 27 proteins differentially expressed between visit 1 and visit 2 were also differentially expressed at visit 3 ( Figure 1B) , with a consistent directionality over time ( Figure 1C) . A box plot of expression of these proteins is shown in Supplementary Figure III .
To address the functional significance of these results, we sought next to understand the tissue of origin for these 19 proteins and the potential functional significance of these proteins to human disease processes via pathway analysis. First, to address the tissues of origin for these 19 differentially abundant proteins postbariatric surgery, we analyzed whole transcriptome RNA-sequencing data from the EMBL-EBI's RNA-Seq Atlas, consisting of 32 tissues from 122 individuals. [17] [18] [19] Figure 2A shows the fold change for these 19 genes between the highest expressing tissue and the next highest expressing tissue in the human RNA-Seq Atlas. Out of the genes corresponding to the 19 proteins, 8 genes had the highest expression in liver relative to other nonsex specific tissues assayed in the RNA-seq Atlas. The list of top 2 tissues expressing these 19 proteins and their corresponding fold changes are presented in Table IV in the online-only Data Supplement.
Given that pathway analytics from 19 proteins may be limited, we expanded the list of candidate targets via the framework discussed in Methods (above). Table V in the online-only Data Supplement lists an expanded list of 26 targets. From these targets, Figure 2B demonstrates the top biological and disease processes specified by these proteins, highlighting major obesity-related cardiometabolic disease illnesses (eg, cerebrovascular disease, coronary artery disease, and hypertension).
Association of Candidate Proteins With Incident Diabetes Mellitus and Metabolic Syndrome in the FHS
Characteristics of FHS participants stratified by new-onset diabetes mellitus or metabolic syndrome are shown in Table VI in the online-only Data Supplement. Among the 4877 diabetes mellitus-free participants at study baseline, 192 (3.9%) developed new-onset diabetes mellitus at an average 6.3 years of follow-up. In contrast to 4685 diabetes mellitus-free participants, those who developed diabetes mellitus during follow-up had significantly lower baseline concentrations of IGFBP-2, IGFBP-1, and PAI-1 (adjusted for age and sex). In multivariable logistic regression for incident diabetes mellitus, only IGFBP-2 was associated negatively with risk of incident diabetes mellitus (Table 2) . Of note, IGFBP-2 increased after bariatric surgery (Table II in the online-only Data Supplement). After we excluded participants with prevalent metabolic syndrome at baseline, we observed an 11% (428 in 4391) incidence of new-onset metabolic syndrome during an average follow-up of 6.3 years. Relative to those participants without metabolic syndrome, individuals who developed metabolic syndrome during follow-up were older and had more significant cardiometabolic risk factors at baseline (eg, higher BMI, glucose, BP), as well as different baseline concentrations of several candidate proteins (higher GMP-140 [granule membrane protein 140], lower IGFBP-1, IGFBP-2; Table VI in the online-only Data Supplement). We observed that a higher concentration of IGFBP-2 at baseline was associated with a lower risk of incident metabolic syndrome after multivariable adjustment (Table 2) .
Discussion
We studied a targeted set of cardiometabolic disease-associated proteins in individuals before and after bariatric surgery, finding a set of proteins altered after early and late postoperative weight loss. Using RNA-sequencing tissue transcriptome data across multiple tissues in healthy individuals, we found that a significant proportion of genes encoding proteins differentially expressed postbariatric surgery were expressed in the liver and adipose tissue, 2 major metabolic tissues known to change with weight loss. Pathway analyses suggested important roles of these genes/proteins in obesity-related CVD, including vascular disease and hypertension. Finally, in a large longitudinal study of individuals in the community, we found that IGFBP-2 (altered after bariatric surgery) was inversely associated with incident metabolic syndrome and diabetes mellitus, after adjusting for established cardiometabolic disease risk factors. Collectively, these findings suggest the utility of discovery efforts rooted in extreme metabolic phenotypes (obesity and weight loss surgery) to implicate known and novel proteins for further mechanistic and prognostic study in obesity. With the advent of rapid, quantitative profiling techniques, there has been a shift from studies characterizing a handful of circulating biomarkers to metabolome-, [20] [21] [22] microbiome-, 23, 24 proteome-, [25] [26] [27] and transcriptome-wide 28 approaches, including integrating all of these technologies. 29 To our knowledge, large studies of individuals undergoing medical or surgical weight loss with monitoring of the plasma proteome have not been published, limiting direct comparison with the results presented here. In a study of serial proteomic alterations 7× during a modest (12%) dietary weight reduction followed weight maintenance in 43 obese subjects, Geyer et al 27 observed decreased plasma abundance of proinflammatory and proinsulin resistance proteins with weight loss (eg, C-reactive protein). In a separate study, Piening et al 29 assessed genomic variation, metabolome, transcriptome, and proteome during dietary weight gain, maintenance, and loss in the same individuals for a 30-to 60-day period. This integrated 29 approach used a similar platform for proteome assessment (Olink) as performed here, with wider coverage. Interestingly, despite subjects entering at a BMI 23 to 25 kg/ m 2 with a 3 kg average excursion during weight loss and maintenance, this study identified 27 proteins (at a false discovery rate of 20%) that were associated with BMI change over time, including MPO (myeloperoxidase) and P-selectin, both of which were identified in our study. There were few similarities in the proteins uncovered in this study and our study, likely owing to the differences in magnitude and duration of weight loss (with surgical versus medical approaches).
Importantly, several proteins in our panel have been previously implicated in obesity and metabolic pathophenotypes in a directionally consistent fashion to what we observed, though large studies reaffirming their relationship with metabolic outcomes remain limited. Although we interrogated a subset of proteins preselected for their involvement in CVD (proprietary panels from Olink), we identified proteins that were known to have dynamic expression with weight change, as well as those not previously known to be responsive to intervention. One of the top targets identified in our study was IGFBP-2. IGFBP-2 expression in the liver is regulated by leptin, 30 a key hormone implicated in obesity and weight change. In turn, increased IGFBP-2 after leptin administration in rodent models of insulin resistance results in decreased hepatic glucose production, 31 L inking weight change, leptin, IGFBP-2, and dysglycemia, a major component of metabolic syndrome. IGFBP-2 expression in mouse models decreases obesity and hypertension and improves insulin sensitivity. 32 In humans, IGFBP-2 may impact visceral fat metabolism (adipogenesis). 33 Consistent with our results in bariatric surgery and a more heterogeneous community study (FHS), lower IGFBP-2 levels have been associated with metabolic syndrome 34 and its phenotypes across the age spectrum 35 and may increase early after bariatric surgery (24 hours), with a sustained response to 1 year. 36 Similarly, CD163 had been associated with visceral fat content and distribution 37 and responds to dietary weight reduction, 38 with recent studies suggesting that inflammatory cell expression of CD163 may be an even more sensitive marker for insulin resistance. 39 Finally, the selectins 40, 41 and PAI-1 42, 43 have well-established associations with obesity, insulin resistance, and responsiveness to interventions The results of an enrichment analysis performed on the set 26 proteins expanded from 19 proteins with differences in terms of pre vs postbariatric surgery are shown here, ranked by a score of −log(P value) *Z score. Three different sources of biological process terms were included: Jensen Disease Ontology (blue), Gene Ontology (gold), and WikiPathways (gray). C1QTNF indicates complement C1q tumor necrosis factor-related protein 1; CNDP1, Beta-Ala-His dipeptidase; COL1A1, collagen alpha-1(I) chain; COMP, cartilage oligomeric matrix protein; CTSD, cathepsin D; FCN2, ficolin-2; GO, gene ontology; IGFBP, insulin-like growth factor binding protein; ITGB2, integrin beta-2; LDLR, low-density lipoprotein receptor; PLAT, the gene encoding the tPA protein (tissue-type plasminogen activator); PON3, paraoxonase-3; RARRES2, retinoic acid receptor responder protein 2; SAA4, serum amyloid A-4 protein; SELE, E-selectin; SELP, P-selectin; SERPINE1, the gene encoding the PAI-1 protein (plasminogen activator inhibitor-1); SPP1, the gene encoding the OPN protein (osteopontin); and TGF, transforming growth factor.
targeting metabolic disease. 44, 45 Although they provide important measure of external validity to the results here, these proteins only encompass a fraction of the overall discovered set in our bariatric cohort (Table III in the online-only Data Supplement). Future investigations in animal systems that target those proteins heretofore not extensively implicated in metabolic disease or obesity previously will provide an important avenue of data for further investigation in both animal and human obesity states.
Our pilot study has several limitations that impact generalizability. Limitations include (1) the fact that we used a preselected manufacturer's protein panel with limited coverage of the proteome that only included those proteins known to be involved in cardiovascular and cardiometabolic disease and (2) the nonrandom selection strategy of nonfasting samples for protein quantification ( Figure I in the onlineonly Data Supplement). The protein discovery in the bariatric surgery cohort was biased; in that, we selected certain panels from the manufacturer that predetermined the set of proteins quantified; as such, we were predestined to identify relevant pathways from vascular disease in our pathway analytics. A more unbiased discovery (eg, mass spectrometry) might have not only uncovered more novel targets but also might have provided coverage of posttranslational protein modifications (potentially relevant in postoperative state). Sample selection in the bariatric study was nonrandom (as described above) and was a small discovery population, which may limit generalizability of the ≥19 targets that were uncovered. In addition, samples were run in 2 batches, with a clear batch effect for which we statistically corrected (alongside a proprietary normalization strategy), though residual batch and normalization effects may remain. Finally, we did not consider split samples across runs (eg, preoperative visit proteins quantified on run 1, whereas postoperative on run 2) to avoid additional noise from normalization. A more ideal study design would have used quantification of all bariatric surgery participants with serial samples at the same time (run) to maximize power and internal validity. Certainly, sample selection in part enriched for insulin resistance, which limits the generalizability of all proteins to the overall benefits of bariatric surgery (eg, on outcome). Future larger studies with a greater range of outcome are necessary to address this important point, as well as detection of lower abundance proteins that may be biologically relevant (but not included due to protein selection scheme here). Finally, given that we observed changes in weight at our early time point and did not specifically investigate the effects of type of bariatric surgery (banding versus bypass), we cannot pinpoint whether the changes observed are because of type of surgery or weight loss. Studies targeting an earlier time point postoperatively would address this important physiological concern. Finally, additional studies that evaluate serial tissue expression across multiple tissue types in humans may help address the tissue of origin for the differentially expressed proteins observed in this study. With regard to the FHS component, FHS independently selected their proteins for quantification, and we did not have the opportunity to validate all of the proteins identified in our bariatric surgery discovery. Despite these limitations, we did demonstrate (1) several directionally consistent relationships in a handful of proteins with incident metabolic diseases in FHS and (2) noted several identified proteins may have prior biological validity in insulin resistance, suggesting generalizability.
In conclusion, using a directed protein quantification platform in a group of individuals before and after bariatric surgery, we identified known and novel proteins altered after surgical weight loss, with implicated roles in cardiovascular and metabolic diseases. One of these proteins-IGFBP-2-was inversely associated with incident metabolic syndrome and diabetes mellitus after adjustment for clinical risk factors in a large population study. These efforts lay the groundwork for large-scale molecular profiling efforts in well-defined obesity interventions and large epidemiological cohorts to define novel targets for investigation, manipulation, and clinical surveillance.
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